New realities of phase I clinical trials in the era of immuno-oncology: the durvalumab experience

Ann Oncol. 2019 Dec 1;30(12):2004-2007. doi: 10.1093/annonc/mdz401.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Clinical Trials, Phase I as Topic
  • Humans
  • Medical Oncology / trends
  • Neoplasms / drug therapy*
  • Neoplasms / immunology
  • Neoplasms / pathology

Substances

  • Antibodies, Monoclonal
  • durvalumab